Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01877499
Other study ID # METc 2013/33
Secondary ID not available ye
Status Completed
Phase N/A
First received June 6, 2013
Last updated March 1, 2017
Start date March 28, 2013
Est. completion date June 30, 2015

Study information

Verified date March 2017
Source VU University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Two recent randomized controlled trials (RCT) on online hemodiafiltration (HDF) did not show a treatment effect on patient survival when compared with low‐ or high‐flux hemodialysis. Interestingly, post‐hoc (on treatment) analyses from both trials unequivocally showed reduced mortality in the patient group achieving the highest convection volumes. Moreover, a third trial recently found a significant 30% decrease in mortality when HDF was applied with a mean convection volume of 23.7 L per session, which was somewhat higher than the average volumes reached in the aforementioned trials. Altogether, these findings support the concept of a dose-response effect, in which a minimally delivered convection volume is required in order to show a survival benefit.

Hence, the question arises whether high convection volumes are achievable in the majority of patients. The aim of this study is thus to test the following hypothesis: high‐volume (>22 liters per treatment) post-dilution on‐line hemodiafiltration (HDF) is achievable in the majority (>75%) of patients treated with chronic intermittent hemodialysis. This will be done through the use of a dedicated standardized protocol, in which the three most important determinants of convection volume will be successively optimized: treatment time, blood flow rate and filtration fraction.


Description:

Hemodialysis (HD) is the most common used renal replacement therapy worldwide. The main objective is the removal of excess fluid and toxic solutes from the patient. Despite the relative efficiency of modern dialyzers, HD remains inferior to normal kidney function, in part because of the inadequate clearance of so-called 'middle molecules'. In other words, 'uremic toxins' accumulate in chronic HD patients.

The role of middle molecular weight uremic toxins in the pathogenesis of many co-morbid conditions associated with end-stage renal disease is increasingly recognized. Hence, the hypothesis that their enhanced removal could convey a better survival has been proposed. Actually, HDF is the most effective modality in terms of solute removal, because solute transport is achieved by both diffusion (especially for small molecules) and convection (the most important clearance route for middle molecules). Although some convective transport can be achieved with high-flux HD, only in HDF can the amount of filtered volume reach values of 20 liters per session or more.

In line with this thinking, two RCTs comparing HDF to standard hemodialysis with either low- or high-flux membranes were performed. However, treatment assignment did not alter the primary outcome of all-cause mortality in neither of them. Interestingly, post‐hoc analyses from both trials unequivocally showed reduced mortality in the patient group achieving the highest convection volumes. Whether these data result from so‐called dose-targeting bias (the healthiest patients reaching the highest volumes) cannot be formally excluded, but it is noteworthy that these results remained after correction for known determinants of mortality. Moreover, careful examination of patients' baseline characteristics of the CONTRAST HDF cohort did not reveal a healthier profile among the high convection volume group.

Recently, a third trial found a significant 30% decrease in mortality when HDF was applied with a mean convection volume of 23.7 L per session, which was somewhat higher than the average volumes reached in the aforementioned trials (respectively 20.7 and 19.5 L per session). Altogether, these findings support the concept of a dose-response effect, in which a minimally delivered convection volume is required in order to show a survival benefit.

Hence, the question arises whether high convection volumes are achievable in the majority of patients. In a previous sub-analysis of CONTRAST, it was found that the most important determinants of achieved convection volume were treatment time and blood flow rate. Moreover, it was noted that convection volumes and filtration fraction (defined as the ratio of extracted plasma water flow rate to blood flow rate) differed markedly per participating center, suggesting different practice patterns. Thus, it is plausible that the optimization of these apparently seemingly modifiable factors, on an individual basis through a dedicated standardized protocol, could translate into a higher achieved convection volume.

The aim of this study is to test the following hypothesis: high‐volume (>22 liters per treatment) post-dilution on‐line hemodiafiltration (HDF) is achievable in the majority (>75%) of patients treated with chronic intermittent hemodialysis.

This study is a prospective observational study, in which all enrolled patients will be treated by post-dilution on-line HDF with the application of a standardized protocol aiming at maximizing the convection volume.

At the beginning of the study, each patient's usual dialysis parameters will serve as starting parameters. In addition, incident HDF patients will start with a filtration fraction of 25 % (or equivalent) on a post‐dilution mode.

Then, convection volume will be increased stepwise by successively optimizing the three most important determining factors. First, treatment time will be increased to 4 h, if possible. Second, blood flow will be increased by 50 mL/min per treatment until a value 400 mL/min is reached, provided that pre-specified safety limits are respected. Third, filtration fraction will be increased by 2% per treatment up to a maximum of 33% or the maximally achieved value within safety limits. To take into account different settings between the various dialysis machines used by the participating centers, an easy-to-use conversion table will be provided to the nursing staff, allowing to find the parameter (substitution flow, substitution volume or substitution ratio) corresponding to the desired filtration fraction.

At the end of the step-up protocol, the achieved convection volume will be assessed and compared to the starting value. Additionally, a follow-up period of 8 weeks, in which the maximum values of the targeted parameters will be kept the same, will be observed in order to assess whether the high convective volumes can be maintained for a longer period.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date June 30, 2015
Est. primary completion date March 6, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients treated with HD or HDF since >6 weeks, 3 times a week;

- Patients able to understand the study procedures;

- Patients willing to provide written informed consent.

Exclusion Criteria:

- Current age < 18 years;

- Severe incompliance to dialysis procedure and accompanying prescriptions (frequency and duration of dialysis treatment and fluid restriction);

- Life expectancy < 3 months due to non-renal disease.

Study Design


Intervention

Other:
Optimization of HDF key parameters
First, patients actually receiving standard dialysis will be switched to post-dilution HDF. Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume. Precisely, the following 3 parameters will successively be increased towards a maximal target: Treatment time (up to 4 hours per session); Blood flow rate (up to 400 mL/min; Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%). Maximal values for these parameters will be those achieved within pre-specified safety limits.

Locations

Country Name City State
Netherlands Academic Medical Center - Dianet Amsterdam
Netherlands Diapriva Dialyse Center Amsterdam
Netherlands VUmc Amsterdam
Netherlands Catharina Hospital Eindhoven
Netherlands Martini Hospital Groningen
Netherlands Maasstad Hospital Rotterdam
Netherlands UMC Utrecht Utrecht

Sponsors (7)

Lead Sponsor Collaborator
VU University Medical Center Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Catharina Ziekenhuis Eindhoven, Diapriva Dialysis Center, Amsterdam, Julius Center, Martini Hospital Groningen, UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

References & Publications (4)

Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators.. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012 Jun;23(6):1087-96. doi: 10.1681/ASN.2011121140. — View Citation

Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group.. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013 Feb;24(3):487-97. doi: 10.1681/ASN.2012080875. Erratum in: J Am Soc Nephrol. 2014 May;25(5):1130. — View Citation

Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M; Turkish Online Haemodiafiltration Study.. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013 Jan;28(1):192-202. doi: 10.1093/ndt/gfs407. — View Citation

Penne EL, van der Weerd NC, Bots ML, van den Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, Ter Wee PM, Blankestijn PJ; CONTRAST investigators.. Patient- and treatment-related determinants of convective volume in post-dilution haemodiafiltration in clinical practice. Nephrol Dial Transplant. 2009 Nov;24(11):3493-9. doi: 10.1093/ndt/gfp265. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with a convection volume of at least 22 liters per treatment At the end of the step-up protocol (within 6 weeks from the start of the study)
Secondary Achieved convection volume At the end of the step-up protocol and after a 8-weeks maintenance phase
Secondary Change in convection volume At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
Secondary Change in other HDF parameters Increase in treatment time, blood flow rate and filtration fraction At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
Secondary Change in dialysis system pressures Change in dynamic venous, arterial, filter entrance and transmembrane pressures during treatment when the maximal convection volume is reached vs. baseline pressure values At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
See also
  Status Clinical Trial Phase
Completed NCT04087213 - Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD N/A
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT02237521 - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease N/A
Withdrawn NCT01691196 - Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Completed NCT01394341 - Liraglutide Treatment to Patients With Severe Renal Insufficiency Phase 4
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4
Completed NCT00307463 - Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Phase 4
Recruiting NCT00155363 - Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Phase 4
Completed NCT00234156 - The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers N/A
Completed NCT00586131 - Arterial pH and Total Body Nitrogen Balances in APD Phase 4
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Recruiting NCT04575077 - The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
Enrolling by invitation NCT05001009 - Goals of Care Conversations Study N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Recruiting NCT03862859 - The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis Phase 4
Terminated NCT03661229 - Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device N/A
Completed NCT03288922 - Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF N/A
Completed NCT02572882 - Gut Microbiome and p-Inulin in Hemodialysis N/A
Completed NCT02360748 - A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients N/A